Baird analyst Collen Kusy lowered the firm’s price target on Iovance Biotherapeutics to $20 from $23 and keeps an Outperform rating on the shares. The firm said they reported 2Q23 results and notably, launch preparedness is coming into view, with many treatment centers already onboarding, and management expects a strong launch. Execution continues on its regulatory strategy in melanoma and lung cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics reports Q2 EPS (47c), consensus (80c)
- Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
- Is IOVA a Buy, Before Earnings?
- Iovance Biotherapeutics call volume above normal and directionally bullish
- Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer